Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NASDAQ:APRE NASDAQ:CYCN NASDAQ:NOVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$9.13-3.7%$8.50$6.51▼$13.27$9.67M1.6513,031 shs4,840 shsAPREAprea Therapeutics$1.86+3.3%$1.74$1.41▼$5.01$10.29M1.1933,751 shs69,081 shsCYCNCyclerion Therapeutics$3.35+6.7%$3.10$1.27▼$9.47$10.75M1.551.27 million shs23,846 shsNOVNNovan$0.00$0.08▼$3.33$2.64M-0.06602,421 shs7.19 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+0.42%+1.01%-6.94%+41.58%+13.33%APREAprea Therapeutics+4.05%+9.09%+2.86%+13.56%-52.88%CYCNCyclerion Therapeutics+1.62%+1.29%-1.26%+24.60%+37.12%NOVNNovan0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.8136 of 5 stars3.54.00.00.02.30.80.6APREAprea Therapeutics2.5069 of 5 stars3.54.00.00.00.00.81.3CYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANOVNNovanN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00228.73% UpsideAPREAprea Therapeutics 3.00Buy$15.50733.33% UpsideCYCNCyclerion Therapeutics 0.00N/AN/AN/ANOVNNovan 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NOVN, ADXN, APRE, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K21.03N/AN/A$10.37 per share0.88APREAprea Therapeutics$1.50M6.86N/AN/A$3.55 per share0.52CYCNCyclerion Therapeutics$2M5.38N/AN/A$3.27 per share1.02NOVNNovan$24.71M0.00N/AN/A$0.19 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A3,584.49%-54.27%-49.15%9/1/2025 (Estimated)APREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)CYCNCyclerion Therapeutics-$3.06M-$1.16N/A∞N/AN/A-34.02%-30.68%8/6/2025 (Estimated)NOVNNovan-$31.31M-$1.32N/AN/AN/A-128.61%-700.28%-39.58%N/ALatest NOVN, ADXN, APRE, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ANOVNNovanN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A3.023.02APREAprea TherapeuticsN/A5.905.90CYCNCyclerion TherapeuticsN/A4.214.21NOVNNovanN/A0.740.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%APREAprea Therapeutics34.19%CYCNCyclerion Therapeutics75.62%NOVNNovan14.51%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%APREAprea Therapeutics13.63%CYCNCyclerion Therapeutics34.30%NOVNNovan1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataCYCNCyclerion Therapeutics303.21 million2.11 millionNo DataNOVNNovan9028.02 million27.65 millionNot OptionableNOVN, ADXN, APRE, and CYCN HeadlinesRecent News About These CompaniesHow Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug marketSeptember 18, 2024 | invezz.comINovartis AGFebruary 27, 2024 | wsj.comNovartis AG Registered SharesFebruary 16, 2024 | morningstar.comMNovartis AG Registered Shares NOVNOctober 31, 2023 | morningstar.comMNovan: Regulation Fd Disclosure, Financial Statements And ExhibitsOctober 25, 2023 | cbonds.comCNovan reaches deals to sell assets in bankruptcy caseSeptember 8, 2023 | bizjournals.comFirm Retention Summary: NovanAugust 8, 2023 | msn.comNovan (NOVN) Price Target Increased by 43.52% to 15.81August 3, 2023 | msn.comNovan files patent for a composition and method of treating skinAugust 1, 2023 | pharmaceutical-technology.comPInsider Sale Alert: Novan Inc. [NOVN] – Is it Time to sell?July 25, 2023 | knoxdaily.comKNOVN short interest surges, indicating growing pessimism among investorsJuly 21, 2023 | knoxdaily.comKNOVN stock rated an Overweight by Cantor FitzgeraldJuly 18, 2023 | knoxdaily.comKNovan Shares Hit 52-Week Low After Bankruptcy DeclarationJuly 17, 2023 | marketwatch.comDurham biotech Novan to sell assets, files for bankruptcyJuly 17, 2023 | wraltechwire.comWPotential Price Increase for Novan Inc. (NOVN) After Recent Insider ActivityJuly 11, 2023 | knoxdaily.comKNovan Inc. [NOVN] Investment Guide: What You Need to KnowJuly 3, 2023 | knoxdaily.comKCIMB appoints Novan Amirudin as CIMB Investment Bank CEOJune 16, 2023 | malaymail.comMCIMB appoints Novan Amirudin as CEO of CIMB Investment BankJune 16, 2023 | thestar.com.myTNovan Amirudin new CIMB Investment Bank CEOJune 16, 2023 | freemalaysiatoday.comFDurham pharma Novan slashes 50% of workforce, mulls sale of assetsJune 1, 2023 | wraltechwire.comWNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNOVN, ADXN, APRE, and CYCN Company DescriptionsAddex Therapeutics NASDAQ:ADXN$9.13 -0.35 (-3.73%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Aprea Therapeutics NASDAQ:APRE$1.86 +0.06 (+3.33%) As of 03:16 PM EasternAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Cyclerion Therapeutics NASDAQ:CYCN$3.35 +0.21 (+6.69%) As of 03:02 PM EasternCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Novan NASDAQ:NOVNNovan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound Rises as Short Sellers Exit and AI Demand Grows Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Robinhood Stock Gets 5 Price Target Upgrades, Signaling Upside AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
